These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27324768)

  • 1. Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.
    Taubert M; Zoller M; Maier B; Frechen S; Scharf C; Holdt LM; Frey L; Vogeser M; Fuhr U; Zander J
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5254-61. PubMed ID: 27324768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
    Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
    Taubert M; Zander J; Frechen S; Scharf C; Frey L; Vogeser M; Fuhr U; Zoller M
    J Antimicrob Chemother; 2017 Aug; 72(8):2304-2310. PubMed ID: 28541510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.
    Zoller M; Maier B; Hornuss C; Neugebauer C; Döbbeler G; Nagel D; Holdt LM; Bruegel M; Weig T; Grabein B; Frey L; Teupser D; Vogeser M; Zander J
    Crit Care; 2014 Jul; 18(4):R148. PubMed ID: 25011656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
    Yagi T; Naito T; Doi M; Nagura O; Yamada T; Maekawa M; Sato S; Kawakami J
    Int J Antimicrob Agents; 2013 Oct; 42(4):329-34. PubMed ID: 23988716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.
    Blackman AL; Jarugula P; Nicolau DP; Chui SH; Joshi M; Heil EL; Gopalakrishnan M
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
    Wu X; Tang Y; Zhang X; Wu C; Kong L
    Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
    Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
    J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of linezolid in critically ill patients.
    Sazdanovic P; Jankovic SM; Kostic M; Dimitrijevic A; Stefanovic S
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):595-600. PubMed ID: 27020789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin.
    Blassmann U; Roehr AC; Frey OR; Koeberer A; Briegel J; Huge V; Vetter-Kerkhoff C
    Pharmacology; 2016; 98(1-2):51-5. PubMed ID: 27046487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.